RT Journal Article
SR Electronic
T1 Clinical feasibility study utilizing multi-sensor devices with the goal of developing remote monitoring digital health solutions for patients with asthma or COPD
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 1358
DO 10.1183/13993003.congress-2020.1358
VO 56
IS suppl 64
A1 Goyal, Pankaj
A1 Calvo, Francesc
A1 Maboudian, Mojdeh
A1 Lyu, Tianmeng
A1 Rinderknecht, Mike
A1 Holzhauer, Bjoern
A1 Plante, Greg
A1 Kelly, Brian
A1 Bacher, Gerald
YR 2020
UL http://erj.ersjournals.com/content/56/suppl_64/1358.abstract
AB Introduction: Using multi-sensor devices in large scale clinical trials may facilitate development of new digital health solutions for remote monitoring and care of patients. Choice of appropriate parameters and devices for use in such clinical trials poses significant technological and operational challenges.Aim: Conduct a technological, operational and clinical feasibility study to determine the most appropriate multi-sensor devices for use in large scale Asthma and COPD clinical trialsMethods: Parameters of clinical relevance to monitor Asthma and COPD patients were shortlisted. Sensor devices were chosen based on required parameter coverage, regulatory status, scientific evidence and technological and operational feasibility. Sensor data was collected and analyzed from 29 patients (moderate to severe COPD or uncontrolled Asthma) in a 4-week observational clinical feasibility study.Results: Parameters with potential clinical relevance (inclusive of heart rate, oxygen saturation, respiratory rate, sleep, physical activity, lung function, FeNO, rescue medication use and environmental data) were assessed using the following devices: Philips Biosensor®, Biovotion®, ActiGraph®, GoSpiro®, NIOX VERO®, MDI Sensor (Propeller Health®) and Emfit® . Patient compliance, burden to patient, usability and data quality, varied between the sensor devices and between asthma and COPD patients.Conclusions: The key considerations for selection of digital sensors for large scale remote monitoring clinical trials are: type and severity of disease, clinically relevant parameters, burden to patient, usability and data-quality of devices.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 1358.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).